Figures (7)  Tables (1)

    • Figure 1. 

      (a) LASSO deviance profiles for miRNAs associated with GC patients in the training group. (b) LASSO coefficient profiles for miRNAs associated with GC patients in the training group.

    • Figure 2. 

      (a) Survival curves of the effect of miRNA-based risk scores on GC patients in the training group. (b) Survival curves of the effect of miRNA-based risk scores on GC patients in the validation group.

    • Figure 3. 

      (a) KEGG enrichment analysis of the miRNAs' target genes. (b) GO pathway enrichment analysis of the miRNAs' target genes.

    • Figure 4. 

      Nomogram for predicting the survival rate of GC patients.

    • Figure 5. 

      (a) Calibration plot of the comparison between the predicted and actual survival probability over 1, 2, and 3 years in the training group. (b) Calibration plot of the comparison between predicted and actual survival probability over 1, 2, and 3 years in the validation group.

    • Figure 6. 

      The predictive effect of the nomogram model, risk score, age, radiotherapy, pharmaceutical therapy, and the tumor's pathological stage in GC patients on OS was evaluated by the C-index.

    • Figure 7. 

      DCA revealed that patients could gain significant benefits from use of the nomogram in clinical decision-making.

    • Variables Training group
      (n = 76)      		 Validation group
      (n = 400)      		 p-value
      Age (years) 67.34 ± 9.46 64.49 ± 11.85 0.05
      Time (days) 1,095.00
      (431.00, 1,095.00)      		 460.00
      (274.75, 782.75)      		 < 0.01
      Status Dead 42 (55.26%) 240 (60.00%) 0.44
      Alive 34 (44.74%) 160 (40.00%)
      Gender Female 21 (27.63%) 139 (34.75%) 0.23
      Male 55 (72.37%) 261 (65.25%)
      Stage I 17 (22.37%) 50 (12.50%) < 0.01
      II 9 (11.84%) 130 (32.50%)
      III 27 (35.53%) 181 (45.25%)
      IV 23 (30.26%) 39 (9.75%)
      Tumor stage 1 12 (15.79%) 16 (4.00%) < 0.01
      2 11 (14.47%) 82 (20.50%)
      3 5 (6.58%) 188 (47.00%)
      4 48 (63.16%) 114 (28.50%)
      Metastasis 0 53 (69.74%) 358 (89.50%) < 0.01
      1 23 (30.26%) 26 (6.50%)
      Unknown 0 (0.00%) 16 (4.00%)
      Spread of cancer to lymph nodes 0 26 (34.21%) 125 (31.25%) < 0.01
      1 7 (9.21%) 105 (26.25%)
      2 18 (23.68%) 81 (20.25%)
      3 25 (32.89%) 84 (21.00%)
      Unknown 0 (0.00%) 5 (1.25%)
      Lauren classification Intestinal 42 (55.26%) 83 (56.08%) 0.12
      Diffuse 29 (38.16%) 63 (42.57%)
      Mixed 5 (6.58%) 2 (1.35%)
      Radiotherapy Not performed 57 (75.00%) 296 (79.36%) 0.40
      Performed 19 (25.00%) 77 (20.64%)
      Pharmaceutical therapy Not performed 31 (40.79%) 188 (50.40%) 0.13
      Performed 45 (59.21%) 185 (49.60%)

      Table 1. 

      Baseline characteristics of GC patients in the training and validation groups